CA2628379A1 - Adminstration routes for priming/boosting with influenza vaccines - Google Patents

Adminstration routes for priming/boosting with influenza vaccines Download PDF

Info

Publication number
CA2628379A1
CA2628379A1 CA002628379A CA2628379A CA2628379A1 CA 2628379 A1 CA2628379 A1 CA 2628379A1 CA 002628379 A CA002628379 A CA 002628379A CA 2628379 A CA2628379 A CA 2628379A CA 2628379 A1 CA2628379 A1 CA 2628379A1
Authority
CA
Canada
Prior art keywords
vaccine
mucosal
influenza
parenteral
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002628379A
Other languages
English (en)
French (fr)
Inventor
Michael Vajdy
Derek O'hagan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines SRL
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2628379A1 publication Critical patent/CA2628379A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55544Bacterial toxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002628379A 2005-11-04 2006-11-06 Adminstration routes for priming/boosting with influenza vaccines Abandoned CA2628379A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US73402605P 2005-11-04 2005-11-04
US60/734,026 2005-11-04
US83633206P 2006-08-07 2006-08-07
US60/836,332 2006-08-07
PCT/GB2006/004132 WO2007052057A2 (en) 2005-11-04 2006-11-06 Adminstration routes for priming/boosting with influenza vaccines

Publications (1)

Publication Number Publication Date
CA2628379A1 true CA2628379A1 (en) 2007-05-10

Family

ID=37862714

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002628379A Abandoned CA2628379A1 (en) 2005-11-04 2006-11-06 Adminstration routes for priming/boosting with influenza vaccines

Country Status (7)

Country Link
US (1) US20100158943A1 (enExample)
EP (1) EP1945253A2 (enExample)
JP (1) JP2009514840A (enExample)
AU (1) AU2006310338A1 (enExample)
CA (1) CA2628379A1 (enExample)
NZ (1) NZ567980A (enExample)
WO (1) WO2007052057A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12258540B2 (en) 2017-10-30 2025-03-25 Takeda Pharmaceutical Company Limited Environmentally compatible detergents for inactivation of lipid-enveloped viruses

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090016704A (ko) 2006-06-15 2009-02-17 노파르티스 아게 보조제-보존 수회-투여 인플루엔자 접종 요법
ES2539818T3 (es) 2007-08-02 2015-07-06 Biondvax Pharmaceuticals Ltd. Vacunas contra la gripe multiepitópicas multiméricas
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
WO2009071633A1 (en) * 2007-12-06 2009-06-11 Glaxosmithkline Biologicals S.A. Influenza composition
EA201071086A1 (ru) 2008-03-18 2011-04-29 Новартис Аг Усовершенствованный способ получения вакцинных антигенов вируса гриппа
WO2009156852A1 (en) * 2008-06-25 2009-12-30 Novartis Ag Rapid responses to delayed booster immunisations
US20120093859A1 (en) 2009-02-10 2012-04-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
EP3173097A3 (en) 2009-02-10 2017-07-12 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
EP2596017B1 (en) * 2010-07-22 2019-04-03 John W. Schrader Cross-protective antibody against influenza viral infection
US9821051B1 (en) 2010-10-28 2017-11-21 Seqirus UK Limited Reducing hospitalization in elderly influenza vaccine recipients
WO2012114323A1 (en) * 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
JP2016502995A (ja) * 2012-12-17 2016-02-01 ユーロシネ ヴァクシンズ アクチエボラーグ 鼻腔内予防接種投薬レジメン
US10335435B2 (en) 2015-05-22 2019-07-02 Marco Merida Method for endoscopically delivering stem cells to the brain using an intranasal, injectable approach
BR112017028011A2 (pt) 2015-06-26 2018-08-28 Seqirus Uk Ltd vacinas de gripe correspondentes antigenicamente

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
US5643574A (en) * 1993-10-04 1997-07-01 Albany Medical College Protein- or peptide-cochleate vaccines and methods of immunizing using the same
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US6818222B1 (en) * 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
JP2003509473A (ja) * 1999-09-24 2003-03-11 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
ATE426412T1 (de) * 2003-01-30 2009-04-15 Novartis Vaccines & Diagnostic Adjuvante influenza-vakzine
US20040213745A1 (en) * 2003-02-20 2004-10-28 Vincent Sullivan Powder formulations of rSEB for improved vaccination

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12258540B2 (en) 2017-10-30 2025-03-25 Takeda Pharmaceutical Company Limited Environmentally compatible detergents for inactivation of lipid-enveloped viruses

Also Published As

Publication number Publication date
US20100158943A1 (en) 2010-06-24
WO2007052057A2 (en) 2007-05-10
NZ567980A (en) 2012-01-12
AU2006310338A1 (en) 2007-05-10
EP1945253A2 (en) 2008-07-23
JP2009514840A (ja) 2009-04-09
WO2007052057A3 (en) 2007-07-12

Similar Documents

Publication Publication Date Title
AU2008269439B2 (en) Low-additive influenza vaccines
US9901630B2 (en) Adjuvant-sparing multi-dose influenza vaccination regimen
CA2671629C (en) Vaccines including antigen from four strains of influenza virus
AU2008331238B2 (en) Vaccination with multiple clades of H5 influenza A virus
AU2007209019A1 (en) Influenza vaccines containing hemagglutinin and matrix proteins
WO2007110776A1 (en) Storage of influenza vaccines without refrigeration
US20100158943A1 (en) Administration routes for priming/boosting with influenza vaccines
CA2628152C (en) Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
HK1143085B (en) Low-additive influenza vaccines
HK1174281A (en) Low-additive influenza vaccines
HK1162312A (en) Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
HK1146577B (en) Vaccination with multiple clades of h5 influenza a virus

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20141106